Switzerland’s Poor Performance In 2010 Heralds Uncertain Future For The Industry
The Swiss pharmaceutical industry is seizing upon the deficit that hit the country's drug sector in 2010 – the first in nearly 50 years – to launch a campaign against policies instigated by the Swiss Federal Office of Public Health (BAG).
You may also be interested in...
The Swiss government and the pharmaceutical industry have reached an agreement that will see prices slashed by 20% over the next three years, but reimbursement decisions to be accelerated by over 300%.
Pricing pressure in Europe is hardly new, but it became a much bigger concern in 2010. The last 18 months have seen some of the most severe and certainly the most numerous, price cuts across the region. Although individual European countries represent only a small share of Big Pharma revenues, the EU as a whole is the world's second-largest market in sales terms, only slightly smaller than the U.S.
For the generic drug industry, 2011 is just about utopia, while for brand drug makers it marks the end of an era. With Pfizer's blockbuster statin Lipitor (atorvastatin) – the world's top-selling drug with more than $11 billion in sales – expected to go generic in the U.S. in November, it marks a symbolic shift from the blockbuster primary care glory days of the late 1990s to the highly genericized, highly fragmented market of today.